Learn about the promising results of triplet therapy in early bladder cancer treatment, offering new hope for patients.

Discover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential ...

Explore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing ...

The phase 3 DeLLphi-305 trial showed tarlatamab plus durvalumab significantly improved overall and progression-free survival ...

Patients with advanced or recurrent endometrial cancer that progresses after platinum-based chemotherapy and immunotherapy have few effective options. New phase 3 data suggest an antibody-drug ...

In October, the U.S. Food and Drug Administration (FDA) granted fast track designation to investigational therapies across a range of cancer types, including lung, prostate, gastrointestinal, and ...

The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

The claudin 18.2 (CLDN18.2)-targeting antibody drug conjugate (ADC) sonesitatug vedotin significantly improved overall survival (OS) in patients with previously treated advanced or metastatic CLDN18.2 ...

Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.

The early promise of therapeutic gold seen in clinical trials of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low, hormone receptor (HR)-positive early-stage ...

Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.